| Literature DB >> 23041079 |
Javier A Bravo1, Marcela Julio-Pieper, Paul Forsythe, Wolfgang Kunze, Timothy G Dinan, John Bienenstock, John F Cryan.
Abstract
In the past few years, intestinal microbiota has emerged as a novel target for the treatment of gut-brain axis alterations. These include functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), which can be comorbid with stress-related psychiatric conditions. Thus, modulation of the microbiota (e.g. with the use of probiotics) could be proposed as a novel strategy not only for the treatment of IBS but also as an adjuvant for psychiatric treatment of anxiety and depression.Entities:
Mesh:
Year: 2012 PMID: 23041079 DOI: 10.1016/j.coph.2012.09.010
Source DB: PubMed Journal: Curr Opin Pharmacol ISSN: 1471-4892 Impact factor: 5.547